Fatih LEVENT, Sadık Volkan EMREN, NİHAN KAHYA EREN, Cem NAZLI, Hamza DUYGU

One year follow-up cardiovascular outcomes of coraxel brand paclitaxel eluting stents: a single center experience

Coraxel (Alvimedica) stents are among those that contain paclitaxel and differ from other paclitaxel eluting stents (PES) in the amount of drug they contain. In this context, it is not known whether the clinical effects of Coraxel stents are different or not. In this study, the clinical effects of Coraxel stents were studied. This study was a single-centered, prospective, non-randomized real life study. Patients to whom stents of Coraxel brand were implanted were followed up in 1-, 3-, 6- and 12-month periods between May 2011 and August 2013 for target lesion revascularization (TLR), stent thrombosis and major cardiovascular events. This study enrolled a total of 78 cases. 82.1% of the cases were male. Average age was 61±11 years. Average stent length was 26.91±11.24 mm, and average stent size was 2.73±0.28 mm. 28% of the patients had TLR, 5 (6%) cases had stent thrombosis, 3 (4%) cases death from all causes, 1 (1%) case cardiac death and 55% of the cases showed major cardiovascular events. TLR, major cardiovascular event and stent thrombosis were observed more frequently in the patients using Coraxel PSS compared to those using TAXUS PSS

PDF

___

1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Ting HH, O'Gara PT, Kushner FG, Ascheim DD, Brindis RG, Casey DE Jr, Chung MK, de Lemos JA, Diercks DB, Fang JC, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of STElevation Myocardial Infarction. J Am Coll Cardiol. 2016;67(10):1235-50.

2. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994;5:S-6.

3. CORAXEL Paclitaxel ElutingCoronaryStentDeliverySystem http://pdf.medicalexpo.com/pdf/alvimedica/coraxel-des/77766- 75086.html access date 01.03.2016

4. Wijns W, Kolh P, Danchin N, DiMario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, SousaUva M, Taggart D. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)1; European Association for Percutaneous CardiovascularI nterventions (EAPCI). Eur Heart J. 2010;31(20):2501-55.

5. Grove E.C., Kristensen S.D. ,.Stent thrombosis: definitions, mechanisms and prevention E-journal of CardiologyPractice,ESC council Volume 5 http://www.escardio.org/Journals/E-Journal-ofCardiology-Practice/Volume-5/Stent-thrombosis-definitionsmechanisms-and-prevention-Title-Stent-thrombos access date 01.03.2016

6. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020- 35.

7. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxeleluting stent for de novo coronary lesions. Circulation. 2003;107(1):38-42.

8. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME; TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108(7):788-94.

9. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Müller R, Regar E, Degertekin M, Ligthart JM, Disco C, Backx B, Russell ME. TAXUS III Trial -in-stent restenosis treated with stent-based delivery of paclitaxel ıncorporated in a slow-release polymer formulation. Circulation. 2003;107(4):559-64.

10. Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DS; TAXUS IV Investigators Long-term safety and efficacy with paclitaxeleluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv. 2009;2(12):1248-59.

11. Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T, Turco MA, Kereiakes DJ, Kelley L, Popma JJ, Russell ME; TAXUS V ISR Investigators. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA. 2006;295(11):1253-63.

12. Grube E1, Dawkins KD, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Buellesfeld L, Koglin J, Russell ME. TAXUS VI 2-yearfollow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. EurHeart J. 2007;28(21):2578-82.

13. Costa JR Jr, Sousa A, Moreira A, Costa R, Cano M, Maldonado G, Campos Neto C, Pavanello R, Egito E, Sousa JE. Insights from the DESIRE registry, the longest (11 years) single center follow-up of a real world population treated exclusively with drug-eluting stents 2013. Europian society of cardiology congress 31-aug-4 sept Amsterdam/Holland p:4837 EurHeart J (2013) 34 (suppl 1).

14. Ong An T.L, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA, Valgimigli M, Sonnenschein K, Regar E, van der Ent M, de Jaegere PP, McFadden EP, Sianos G, van der Giessen WJ, de Feyter PJ, van Domburg RT. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population One-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol. 2005;45(7):1135-41.

15. Lasala JM, Cox DA, Dobies D, Muhlestein JB, Katopodis JN, Revtyak G, Baim DS; ARRIVE 1 Participating Physicians. Usage patterns and 2-year outcomes with the TAXUS Express Stent: Results of the US ARRIVE 1 Registry. Catheter Cardiovasc Interv. 2008;72(4):433-45.

16. Costa JR Jr, Sousa A, Moreira A, Costa R, Cano M, Maldonado G. Ten year follow up of the desire registry: a single –centreperspective on drud eluting stents a decadelater. J Am Coll Cardiol. 2012;59:324.

17. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115:1051105-8.